Mechanical unloading promotes myocardial energy recovery in human heart failure

Circulation: Cardiovascular Genetics

Volumn 7, Issue 3, 2014, Pages 266-276

  Gupte, Anisha A ^a,c   Hamilton, Dale J ^a,b,c   Cordero Reyes, Andrea M ^a,c   Youker, Keith A ^a,c   Yin, Zheng ^a,c   Estep, Jerry D ^a,c   Stevens, Robert D ^d   Wenner, Brett ^d   Ilkayeva, Olga ^d   Loebe, Matthias ^a,c   Peterson, Leif E ^a,c   Lyon, Christopher J ^a,c   Wong, Stephen T C ^a,b,c   Newgard, Christopher B ^d   Torre Amione, Guillermo ^a,c,e   Taegtmeyer, Heinrich ^f   Hsueh, Willa A ^a,b,c  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Heart failure; Metabolism; Mitochondria

Indexed keywords

ACYLCARNITINE; ESTROGEN RELATED RECEPTOR ALPHA; ESTROGEN RELATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PYRUVIC ACID; STEROID RECEPTOR; UNCLASSIFIED DRUG; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; BIOGENESIS; CHILD; CITRIC ACID CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; FATTY ACID OXIDATION; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEART FAILURE; HEART LEFT VENTRICLE WALL; HEART RIGHT VENTRICLE FAILURE; HUMAN; HUMAN TISSUE; LEFT VENTRICULAR ASSIST DEVICE; MALE; METABOLOMICS; MITOCHONDRIAL GENE; MITOCHONDRIAL RESPIRATION; OXIDATION; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; AGED; ENERGY METABOLISM; GENE EXPRESSION PROFILING; GENETICS; HEART ASSIST DEVICE; HEART MUSCLE; HEART MUSCLE CELL; HEART VENTRICLE; METABOLISM; MIDDLE AGED;

ADULT; AGED; ENERGY METABOLISM; FEMALE; GENE EXPRESSION PROFILING; HEART FAILURE; HEART VENTRICLES; HEART-ASSIST DEVICES; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; MYOCYTES, CARDIAC; TRANSCRIPTION FACTORS;

EID: 84903635728     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.113.000404     Document Type: Article

References (45)

1. Jhund PS, Macintyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A, et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation. 2009;119:515-523.
2. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
3. Stewart S, Ekman I, Ekman T, Odén A, Rosengren A. Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004). Circ Cardiovasc Qual Outcomes. 2010;3:573-580.
4. Estep JD, Chang SM, Bhimaraj A, Torre-Amione G, Zoghbi WA, Nagueh SF. Imaging for ventricular function and myocardial recovery on nonpulsatile ventricular assist devices. Circulation. 2012;125:2265-2277.
5. Ambardekar AV, Walker JS, Walker LA, Cleveland JC Jr., Lowes BD, Buttrick PM. Incomplete recovery of myocyte contractile function despite improvement of myocardial architecture with left ventricular assist device support. Circ Heart Fail. 2011;4:425-432.
6. Turer AT, Stevens RD, Bain JR, Muehlbauer MJ, van der Westhuizen J, Mathew JP, et al. Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. Circulation. 2009;119:1736-1746.
7. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009;9:311-326.
8. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 2008;7:45-56.
9. Caglayan E, Stauber B, Collins AR, Lyon CJ, Yin F, Liu J, et al. Differential roles of cardiomyocyte and macrophage peroxisome proliferator-Activated receptor gamma in cardiac fibrosis. Diabetes. 2008;57:2470-2479.
10. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation. 2001;104:2923-2931.
11. Brouilette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J, et al; West of Scotland Coronary Prevention Study Group. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet. 2007;369:107-114.
12. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545- 15550.
13. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289-300.
14. McDaniel HG, Jenkins R, Yeh M, Razzaque A. Glutamic dehydrogenase from rat heart mitochondria. II. Kinetic characteristics. J Mol Cell Cardiol. 1984;16:303-309.
15. McDaniel HG, Jenkins R, McDaniel R. Conditions for glutamate dehydrogenase activity in heart mitochondria. Biochem Med Metab Biol. 1993;50:75-84.
16. Russell RR III, Taegtmeyer H. Changes in citric acid cycle flux and anaplerosis antedate the functional decline in isolated rat hearts utilizing acetoacetate. J Clin Invest. 1991;87:384-390.
17. Villeneuve C, Guilbeau-Frugier C, Sicard P, Lairez O, Ordener C, Duparc T, et al. p53-PGC-1α pathway mediates oxidative mitochondrial damage and cardiomyocyte necrosis induced by monoamine oxidase-A upregulation: role in chronic left ventricular dysfunction in mice. Antioxid Redox Signal. 2013;18:5-18.
18. Sahin E, Colla S, Liesa M, Moslehi J, Müller FL, Guo M, et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature. 2011;470:359-365.
19. Neubauer S. The failing heart -An engine out of fuel. N Engl J Med. 2007;356:1140-1151.
20. Birks EJ, George RS, Hedger M, Bahrami T, Wilton P, Bowles CT, et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation. 2011;123:381-390.
21. Drakos SG, Kfoury AG, Selzman CH, Verma DR, Nanas JN, Li DY, et al. Left ventricular assist device unloading effects on myocardial structure and function: current status of the field and call for action. Curr Opin Cardiol. 2011;26:245-255.
22. Ambardekar AV, Buttrick PM. Reverse remodeling with left ventricular assist devices: a review of clinical, cellular, and molecular effects. Circ Heart Fail. 2011;4:224-233.
23. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al; HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-2251.
24. Razeghi P, Young ME, Ying J, Depre C, Uray IP, Kolesar J, et al. Downregulation of metabolic gene expression in failing human heart before and after mechanical unloading. Cardiology. 2002;97:203-209.
25. de Weger RA, Schipper ME, Siera-de Koning E, van der Weide P, van Oosterhout MF, Quadir R, et al. Proteomic profiling of the human failing heart after left ventricular assist device support. J Heart Lung Transplant. 2011;30:497-506.
26. Bricker DK, Taylor EB, Schell JC, Orsak T, Boutron A, Chen YC, et al. A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science. 2012;337:96-100.
27. Rosenfeld G. Ueber die Behandlung der Zuckerkrankheit. Berliner Klinische Wockenschrift. 1909;46:957-961.
28. Russell RR III, Taegtmeyer H. Pyruvate carboxylation prevents the decline in contractile function of rat hearts oxidizing acetoacetate. Am J Physiol. 1991;261(6 pt 2):H1756-H1762.
29. Taegtmeyer H, Hems R, Krebs HA. Utilization of energy-providing substrates in the isolated working rat heart. Biochem J. 1980;186:701-711.
30. Garnier A, Zoll J, Fortin D, N'Guessan B, Lefebvre F, Geny B, et al. Control by circulating factors of mitochondrial function and transcription cascade in heart failure: a role for endothelin-1 and angiotensin II. Circ Heart Fail. 2009;2:342-350.
31. Sihag S, Cresci S, Li AY, Sucharov CC, Lehman JJ. PGC-1alpha and ERRalpha target gene downregulation is a signature of the failing human heart. J Mol Cell Cardiol. 2009;46:201-212.
32. Karamanlidis G, Nascimben L, Couper GS, Shekar PS, del Monte F, Tian R. Defective DNA replication impairs mitochondrial biogenesis in human failing hearts. Circ Res. 2010;106:1541-1548.
33. Karamanlidis G, Bautista-Hernandez V, Fynn-Thompson F, Del Nido P, Tian R. Impaired mitochondrial biogenesis precedes heart failure in right ventricular hypertrophy in congenital heart disease. Circ Heart Fail. 2011;4:707-713.
34. Aubert G, Vega RB, Kelly DP. Perturbations in the gene regulatory pathways controlling mitochondrial energy production in the failing heart. Biochim Biophys Acta. 2013;1833:840-847.
35. Schilling J, Kelly DP. The PGC-1 cascade as a therapeutic target for heart failure. J Mol Cell Cardiol. 2011;51:578-583.
36. Lehman JJ, Boudina S, Banke NH, Sambandam N, Han X, Young DM, et al. The transcriptional coactivator PGC-1alpha is essential for maximal and efficient cardiac mitochondrial fatty acid oxidation and lipid homeostasis. Am J Physiol Heart Circ Physiol. 2008;295:H185-H196.
37. Huss JM, Imahashi K, Dufour CR, Weinheimer CJ, Courtois M, Kovacs A, et al. The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload. Cell Metab. 2007;6:25-37.
38. Violante S, Ijlst L, van Lenthe H, de Almeida IT, Wanders RJ, Ventura FV. Carnitine palmitoyltransferase 2: new insights on the substrate specificity and implications for acylcarnitine profiling. Biochim Biophys Acta. 2010;1802:728-732.
39. Alaynick WA, Kondo RP, Xie W, He W, Dufour CR, Downes M, et al. ERRgamma directs and maintains the transition to oxidative metabolism in the postnatal heart. Cell Metab. 2007;6:13-24.
40. Riehle C, Wende AR, Zaha VG, Pires KM, Wayment B, Olsen C, et al. PGC-1β deficiency accelerates the transition to heart failure in pressure overload hypertrophy. Circ Res. 2011;109:783-793.
41. Aubert G, Vega RB, Kelly DP. Perturbations in the gene regulatory pathways controlling mitochondrial energy production in the failing heart. Biochim Biophys Acta. 2013;1833:840-847.
42. Leri A, Franco S, Zacheo A, Barlucchi L, Chimenti S, Limana F, et al. Ablation of telomerase and telomere loss leads to cardiac dilatation and heart failure associated with p53 upregulation. EMBO J. 2003;22:131-139.
43. Toko H, Takahashi H, Kayama Y, Oka T, Minamino T, Okada S, et al. Ca2+/ calmodulin-dependent kinase IIdelta causes heart failure by accumulation of p53 in dilated cardiomyopathy. Circulation. 2010;122:891-899.
44. Oeseburg H, de Boer RA, van Gilst WH, van der Harst P. Telomere biology in healthy aging and disease. Pflugers Arch. 2010;459:259-268.
45. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 2007;446:444-448.